February 28th marks Rare Disease Day. In keeping with the theme, EPM asked Dr. Asma Patel of Quotient Sciences what barriers remain in rare disease drug development and the strategies that can bring the much-needed drugs to market faster.
Marcelo Cruz, vice president, Business Development & Marketing at Tjoapack, examines the trends that will impact drug development and the pharma packaging sector in 2023.
A digestive supplement known as, JUVIA Digestive Balance Formula, has recently been launched to treat people with IBS, powered by plants and backed up by science.
Dr. Karen Rowland Yeo, senior vice president, Client & Regulatory Strategy, Certara UK, describes how pioneering biosimulation is helping to predict drug exposures during pregnancy, providing opportunities for safer care and better outcomes.
Almac Pharma Services’ VP Technical Operations, John McQuaid, discusses some growing requirements he sees from Almac’s client base as the industry addresses some of the trends associated with small molecule drug development.
Lonza's Conrad Roten and David Lyon explain why integrated drug substance and drug product services can help shorten First-In-Human (FIH) trial and drug commercialisation timelines.
Subhro Mallik, senior vice president, head of Life Sciences, Infosys explores how advances in data and technology had help with the development of future drugs.
Pamela Spicer, principal analyst at Informa Pharma Intelligence looks at Biogen's recently approved Alzheimer's drug and questions its rollout in countries outside of the US.
European Pharmaceutical Manufacturer speaks to Dr Henry Skinner, CEO of the AMR Action Fund about dangers of AMR, why new incentives are needed for antibiotic development and what the Fund is doing to bring about new antibiotics.
EPM speaks to Shorla Pharma’s CTO Orlaith Ryan about how the company is aiming to be a strong contender in the oncology market through therapies designed for women and children.
Dr Steven Fox, CEO and chairman of biopharmaceutical company Akelos speaks to EPM about how his company wants to tackle the opioid epidemic through the development of non-addictive drugs.
